Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Overlook Novavax at the Risk of Incurring an Opportunity Cost

By Josh Enomoto, InvestorPlace Contributor

Although Pfizer and Moderna have stolen the headlines, there are still ample opportunities for upside with NVAX stock.

It’s Time for iBio Speculators to Consider Something Else

By Josh Enomoto, InvestorPlace Contributor

One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibilities.

Exxon Mobil Is Breathing Through Temporary Air Pockets

By Josh Enomoto, InvestorPlace Contributor

As a transition in power suggests a return to political normalcy, XOM stock and other oil names have jumped higher. However, the broader trend continues to cast a dark cloud over the traditional energy sector.

Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand

By Josh Enomoto, InvestorPlace Contributor

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.

If You Must Trade Hertz, Always Buy on Tuesday

By Josh Enomoto, InvestorPlace Contributor

For nearly everyone, Hertz stock is something you shouldn’t even think about. However, for the rare and intrepid few, HTZGQ could possibly make a case for stakeholder profitability.

8 Stocks to Sell After the Presidential Election

By Josh Enomoto, InvestorPlace Contributor

With the drama over the presidential election appearing to come to a close, these companies may represent stocks to sell as the Biden administration forges a new direction for the country.

Why Online Dating in China Is Much Better for Momo Stock

By Josh Enomoto, InvestorPlace Contributor

With coronavirus cases spiking in many countries, you might be tempted to overlook Momo stock but that might be a mistake.

Teladoc Is the No. 1 Telehealth Stock to Buy

By Josh Enomoto, InvestorPlace Contributor

With coronavirus cases worsening, the bullish narrative for TDOC stock seemingly is never better. Still, there are longer-term reasons to consider Teladoc Health.

9 OTC Stocks With Plenty of Potential

By Josh Enomoto, InvestorPlace Contributor

No one should ever bet on OTC stocks without serious consideration about their risk profile. However, if you know what you’re getting involved in, this much-maligned sector could offer a path to significant growth.

You’re Probably Asking the Wrong Question About Li Auto

By Josh Enomoto, InvestorPlace Contributor

On paper, LI stock seems like a great bet on the wildly explosive EV market in China. But you should check under the hood first.

Load More